Heart failure with reduced ejection fraction (HFrEF) remains associated with high morbidity and mortality, poor quality of life (QoL) and significant exercise limitation. Sympatho-vagal imbalance has been shown to predict adverse prognosis and symptoms in HFrEF, yet it has not been specifically targeted by any guideline-recommended device therapy to date. Barostim™, which directly addresses this imbalance, is the first Food and Drug Administration approved neuromodulation technology for HFrEF. We aimed to analyse all randomized trial evidence to evaluate the effect of baroreflex activation therapy (BAT) on heart failure symptoms, QoL and N-terminal pro-brain natriuretic peptide (NT-proBNP) in HFrEF.

中文翻译：

---

使用 Barostim™ 装置治疗射血分数降低的心力衰竭患者的压力反射激活疗法：随机对照试验的患者水平荟萃分析

射血分数降低的心力衰竭 (HFrEF) 仍然与高发病率和死亡率、低生活质量 (QoL) 和显着的运动受限有关。交感神经-迷走神经失衡已被证明可以预测 HFrEF 的不良预后和症状，但迄今为止，任何指南推荐的设备治疗都没有专门针对它。直接解决这种不平衡的 Barostim ™是食品和药物管理局批准的第一个用于 HFrEF 的神经调节技术。我们旨在分析所有随机试验证据，以评估压力反射激活疗法 (BAT) 对 HFrEF 患者心力衰竭症状、QoL 和 N 末端脑利钠肽原 (NT-proBNP) 的影响。